3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Neoplasms
2
Neoplasm Metastasis
2
Pancreatic Neoplasms
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Gallbladder Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Breast Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
Gemcitabine
205
130-nm albumin-bound paclitaxel
84
Albumin-Bound Paclitaxel
57
pembrolizumab
43
Fluorouracil
41
Leucovorin
34
Oxaliplatin
33
Capecitabine
25
Nivolumab
22
Irinotecan
19
Bevacizumab
17
Paclitaxel
16
Cyclophosphamide
15
Cetuximab
15
Taxes
13
Erlotinib Hydrochloride
13
Drug Therapy
13
Carboplatin
12
irinotecan sucrosofate
11
Injections
10
Cisplatin
9
fludarabine
8
ALT-803
8
spartalizumab
7
olaparib
7
avelumab
7
Pemetrexed
7
Docetaxel
7
ruxolitinib
6
TH 302
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Pancreatic Neoplasms
×
merestinib
×
Clear all
NCT02791334
2024-09-27
PACT
Eli Lilly and Company
Phase 1
Completed
164 enrolled